Monday 13th November 2017
|Text too small?|
Fisher and Paykel Healthcare Corp has won a patent case against ResMed in the UK in the ongoing intellectual property dispute for its face and nasal masks across various jurisdictions.
The High Court of Justice, Chancery Division, Patents Court ruled a disputed ResMed patent was invalid, with the New Zealand manufacturer entitled to recover its legal costs with the amount yet to be determined by the court, the company said in a statement.
“While today’s ruling is just one more step on the journey, it reinforces our confidence in our position and we are satisfied with progress so far,” chief executive Lewis Gradon said.
In 2016, F&P Healthcare claimed that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed counterclaimed for infringement but did eventually revoke two of the patents, leaving only one before the court.
ResMed argued that patent EP 2 708 258 B1 was infringed by two of F&P Healthcare’s masks used for obstructive sleep apnea therapy, the Eson and Simplus masks. Had the patent been valid it would have been infringed. However, "the court found that the patent was invalid in its entirety." F&P Healthcare said.
Subject to any appeal, this European patent will be revoked in the UK and "this result confirms that UK patients can continue to purchase and enjoy the benefits of our high-performance masks," the New Zealand company said.
The skirmish is the latest in a far-ranging dispute between the two firms, with legal action spanning from North America to Europe to New Zealand.
In October F&P Healthcare said that the Regional Court in Munich had ruled ResMed did not infringe its patents on a German utility model patent. A further case is before the same court regarding another patent with a ruling expected in 2018, pending proceedings filed by F&P Healthcare in the European Patent Office.
In its annual report, F&P Healthcare said it had absorbed pre-tax patent litigation costs of $20.7 million during the year to March 31 and it expects to incur litigation-related expenses at a similar run-rate during the 2018 financial year.
F&P Healthcare shares slipped 0.1 percent to $13.20 but have gained 55 percent so far this year.
No comments yet
NZ dollar stalled; US-China trade deal may be postponed
AFT Pharmaceuticals starts to hit its straps
Crown seeks US$100m from Tui operator; Prospector moving on
Pacific Edge goes back to shareholders for another $20m
Crown seeks $100m from Tui operator Tamarind
Ryman underlying annual profit may rise by up to 17%
NZ dollar eases on increasing US-China doubts, lack of news in Fed minutes
From dog tucker to top dog: economists ask how Northport can be Auckland’s best replacement
MARKET CLOSE: NZ shares rise; Metlife jumps on takeover talk
NZ dollar eases on technical factors, buoyed by higher dairy prices